Clinical Trial

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

Study acronym: REaKT-SD
Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
This study is a randomized open-label single-blind non-inferiority comparative effectiveness study of ECT vs. KET for the treatment of Acute Suicidal Depression (ASD).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-09-11; most recent amendment 2025-12-08.
Status change: Not Yet Recruiting → Enrolling by Invitation 2024-01-18
Trial Details
NCT Number NCT06034821
Lead Sponsor Brigham and Women's Hospital
Collaborators: Johns Hopkins University, University of Pittsburgh, The Cleveland Clinic, Icahn School of Medicine at Mount Sinai, University of Toronto, The University of Texas Health Science Center, Houston, UT Health, Mclean Hospital, Massachusetts General Hospital, University of Utah, UC San Francisco
Conditions Acute Suicidal Depression (ASD)
Enrollment 1,500 participants
Start Date 2023-10-01
Primary Completion 2030-10-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-15